A “skinny label” is one way that a generic drug can be commercialized in the US when only a subset of the brand’s uses lose exclusivity. The recent Supreme Court decision in the Caraco case may put a spotlight on the opportunities for “skinny label” generics. The article found here describes some of the issues and possible policy implications that may be associated with an increased use of “skinny labels.”
Prioritising Alzheimer’s disease policy in Europe: Insights from oncology
However, current levels of policy development do not reflect the urgency for change, especially given the progress made in understanding the disease and new...